Exploration of the Antimicrobial Effects of Benzothiazolylthiazolidin-4-One and In Silico Mechanistic Investigation
2021
Аутори:
Haroun, MichelyneTratrat, Christophe
Petrou, Anthi
Geronikaki, Athina
Ivanov, Marija
Ćirić, Ana
Soković, Marina
Nagaraja, Sreeharsha
Narayanaswamy Venugopala, Katharigatta
Balachandran Nair, Anroop
Elsewedy, Heba
Kochkar, Hafedh
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Background: Infectious diseases still affect large populations causing significant morbidity
and mortality. Bacterial and fungal infections for centuries were the main factors of death and
disability of millions of humans. Despite the progress in the control of infectious diseases, the
appearance of resistance of microbes to existing drugs creates the need for the development of new
effective antimicrobial agents. In an attempt to improve the antibacterial activity of previously
synthesized compounds modifications to their structures were performed. Methods: Nineteen
thiazolidinone derivatives with 6-Cl, 4-OMe, 6-CN, 6-adamantan, 4-Me, 6-adamantan substituents at
benzothiazole ring were synthesized and evaluated against panel of four bacterial strains S. aureus,
L. monocytogenes, E. coli and S. typhimirium and three resistant strains MRSA, E. coli and P. aeruginosa
in order to improve activity of previously evaluated 6-OCF3
-benzothiazole-based thiazolidinones.
The evaluation of minimum inhibitory and minimum bactericidal concentration was determined by
microdilution method. As reference compounds ampicillin and streptomycin were used. Results:
All compounds showed antibacterial activity with MIC in range of 0.12–0.75 mg/mL and MBC at
0.25–>1.00 mg/mL The most active compound among all tested appeared to be compound 18, with
MIC at 0.10 mg/mL and MBC at 0.12 mg/mL against P. aeruginosa. as well as against resistant strain
P. aeruginosa with MIC at 0.06 mg/mL and MBC at 0.12 mg/mL almost equipotent with streptomycin
and better than ampicillin. Docking studies predicted that the inhibition of LD-carboxypeptidase is
probably the possible mechanism of antibacterial activity of tested compounds. Conclusion: The best
improvement of antibacterial activity after modifications was achieved by replacement of 6-OCF3
substituent in benzothiazole moiety by 6-Cl against S. aureus, MRSA and resistant strain of E. coli by
2.5 folds, while against L. monocytogenes and S. typhimirium from 4 to 5 folds.
Кључне речи:
thiazolidinones; PASS; antibacterial; MIC/MFC; docking; LD-carboxypeptidaseИзвор:
Molecules, 2021, 26, 13, 4061-Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200007 (Универзитет у Београду, Институт за биолошка истраживања 'Синиша Станковић') (RS-MESTD-inst-2020-200007)
- Deanship of Scientific Research of King Faisal University, Saudi Arabia (1811019)
DOI: 10.3390/molecules26134061
ISSN: 1420-3049
PubMed: 34279400